A new peer-reviewed study published in Diabetes, Obesity and Metabolism compared once-daily oral semaglutide 25 mg to subcutaneous semaglutide 2.4 mg — the injectable dose used in Wegovy — for weight management in people with obesity, including those with type 2 diabetes. The research adds important data as pill-form semaglutide gains regulatory traction.
Why This Study Matters
Semaglutide has already been approved as a subcutaneous injection for weight management and cardiovascular disease risk reduction. More recently, an oral formulation of semaglutide has also received approval. However, according to the study's authors, there has been limited information available across oral dose levels — and critically, no prior studies specifically examined the 25 mg oral dose in people living with both obesity and type 2 diabetes. This research was designed to help fill that gap using a model-informed drug development approach, a method that uses pharmacokinetic and pharmacodynamic modeling to estimate drug behavior and outcomes.
What the Research Approach Involved
Rather than a traditional head-to-head clinical trial, the researchers used a model-informed drug development (MIDD) framework. This scientific method integrates existing pharmacokinetic (PK) data — how the drug is absorbed, distributed, and processed by the body — to predict and compare how oral and injectable semaglutide perform across different patient populations. The study examined efficacy, safety, and pharmacokinetics of once-daily oral semaglutide 25 mg relative to subcutaneous semaglutide 2.4 mg, including in patients who have type 2 diabetes alongside obesity, a population that had not previously been studied at this oral dose level.
Key takeaway: This is the first study to model how oral semaglutide 25 mg compares to the Wegovy injection dose specifically in people with both obesity and type 2 diabetes — a common and underrepresented combination in prior semaglutide pill research.
What This Could Mean for Patients
For people who are hesitant about weekly injections, a once-daily pill option is appealing. The existence of an approved oral semaglutide formulation, and growing research into higher oral doses like 25 mg, suggests that needle-free options for meaningful weight management may continue to expand. However, patients should understand that oral and injectable semaglutide are not interchangeable products — they have different pharmacokinetic profiles, dosing requirements, and approved indications. Any switch between formulations should only happen under direct medical supervision.
What to Watch Next
This modeling study sets the stage for future clinical trials that may formally evaluate oral semaglutide 25 mg in people with type 2 diabetes and obesity. As regulatory agencies and manufacturers assess data from studies like this one, higher oral doses could potentially move through the approval pipeline. Patients and clinicians should watch for announcements from Novo Nordisk, the maker of semaglutide products, regarding any new trial launches or submissions based on this emerging evidence base.
Frequently Asked Questions
As research into oral semaglutide doses continues to evolve, it's important to make treatment decisions based on your personal health history and goals. Speak with your prescriber before making any changes to your current GLP-1 medication regimen.
- Peer-reviewed journal article, 'Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach,' Diabetes, Obesity and Metabolism journal.